Impacto do tipo de fibrilhac¸ão auricular no contexto das síndromes coronárias agudas: características clínicas e prognóstico by Galvão-Braga, C et al.




Portuguese Journal of Cardiology
ORIGINAL ARTICLE
Impact  of atrial  fibrillation  type  during  acute  coronary
syndromes: Clinical  features  and  prognosis
Carlos Galvão Braga ∗, Vítor Ramos, Juliana Martins, Carina Arantes,
Glória  Abreu, Catarina Vieira, Alberto Salgado, António Gaspar, Pedro Azevedo,
Miguel Álvares Pereira, Sónia Magalhães, Jorge Marques
Serviço  de  Cardiologia,  Hospital  de  Braga,  Braga,  Portugal
Received  17  June  2014;  accepted  1  January  2015







Introduction:  Atrial  fibrillation  (AF)  is  widely  recognized  as  an  adverse  prognostic  factor  during
acute myocardial  infarction,  although  the  impact  of  AF  type  --  new-onset  (nAF)  or  pre-existing
(pAF) --  is  still  controversial.
Objectives:  To  identify  the  clinical  differences  and  prognosis  of  nAF  and  pAF  during  acute
coronary syndromes  (ACS).
Methods:  We  performed  a  retrospective  observational  cohort  study  including  1373  consecutive
patients (mean  age  64  years,  77.3%  male)  admitted  to  a  single  center  over  a  three-year  period,
with a  six-month  follow-up.
Results:  AF  rhythm  was  identified  in  14.5%  patients,  of  whom  71.4%  presented  nAF  and  28.6%
pAF. When  AF  types  were  compared,  patients  with  nAF  more  frequently  presented  with  ST-
elevation ACS  (p=0.003).  Patients  with  pAF,  in  turn,  were  older  (p=0.032),  had  greater  left
atrial diameter  (p=0.001)  and  were  less  likely  to  have  significant  coronary  lesions  (p=0.034).
Regarding  therapeutic  strategy,  nAF  patients  were  more  often  treated  by  rhythm  control  during
hospital  stay  (p<0.001)  and  were  less  often  anticoagulated  at  discharge  (p=0.001).  Compared
with the  population  without  AF,  nAF  was  a  predictor  of  death  during  hospital  stay  in  univariate
(p<0.001) and  multivariate  analysis  (OR  2.67,  p=0.047),  but  pAF  was  not.  During  follow-up,
pAF was  associated  with  higher  mortality  (p=0.014),  while  nAF  patients  presented  only  a  trend
towards worse  prognosis.
Conclusions:  AF  during  the  acute  phase  of  ACS  appears  to  have  a  negative  prognostic  impact
only in  patients  with  nAF  and  not  in  those  with  pAF.
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reserved.
∗ Corresponding author.
E-mail address: carlos.galvaobraga@gmail.com (C.G. Braga).
http://dx.doi.org/10.1016/j.repc.2015.01.010
0870-2551/© 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.21 4 049
Document downloaded from http://www.elsevier.pt, day 01/07/2015. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.






Impacto  do  tipo  de  fibrilhação  auricular  no  contexto  das  síndromes  coronárias
agudas  --  características  clínicas  e  prognóstico
Resumo
Introdução:  A  fibrilhação  auricular  (FA)  é  um  reconhecido  fator  de  mau  prognóstico  no  enfarte
agudo do  miocárdio,  no  entanto,  o  impacto  do  tipo  de  FA,  de  novo  (FAn)  ou  pré-existente  (FAp),
é ainda  controverso.
Objetivos:  Identificar  as  diferenças  clínicas  e  o  prognóstico  da  FAn  e  da  FAp  nas  síndromes
coronárias  agudas  (SCA).
Métodos:  Estudo  retrospetivo  observacional  de  coorte,  incluindo  1373  doentes  consecutivos
(idade média  64  anos,  77,3%  homens)  com  SCA,  admitidos  num  hospital,  ao  longo  de  três  anos,
com follow-up  de  seis  meses.
Resultados:  A  FA  foi  identificada  em  14,5%  doentes,  dos  quais  71,4%  tinham  FAn  e  28,6%  FAp.
Comparando  os  tipos  de  FA,  verificou-se  que  os  doentes  com  FAn  apresentaram  mais  frequente-
mente SCA  com  elevação  do  segmento  ST  (p=0,003).  Por  sua  vez,  a  FAp  foi  mais  comum  em
doentes  idosos  (p=0,032),  com  diâmetro  superior  da  aurícula  esquerda  (p=0,001)  e  ausência  de
doença coronária  (p=0,034).  Quanto  à  estratégia  terapêutica,  os  doentes  com  FAn  foram  mais
vezes submetidos  a  controlo  de  ritmo  durante  o  internamento  (p<0,001),  mas  menos  hipocoa-
gulados à  alta  (p=0,001).  Quando  comparada  com  a  população  sem  FA,  a  FAn  foi  preditora  de
morte hospitalar  na  análise  univariada  (p<0,001)  e  multivariada  (OR  2,67,  p=0,047),  enquanto  a
FAp não.  Já  no  follow-up,  a  FAp  associou-se  a  maior  mortalidade  (p=0,014),  enquanto  os  doentes
com FAn  apresentaram  apenas  uma  tendência  para  um  pior  prognóstico.
Conclusões:  O  impacto  prognóstico  negativo  da  FA  na  fase  aguda  das  SCA  parece  ocorrer  apenas
nos doentes  que  apresentam  FAn  e  não  naqueles  com  FAp.
© 2014  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
direitos reservados.
Introduction
Atrial  fibrillation  (AF)  frequently  complicates  the  clinical
course  of  acute  myocardial  infarction  (AMI),  with  a  reported
incidence  between  6  and  21%.1 Although  this  arrhythmia  is  a
well-established  independent  predictor  of  mortality  in  the
short  and  long  term  after  AMI,2--4 the  impact  of  the  spe-
cific  AF  type  --  new-onset  or  pre-existing  --  may  be  different.
Few  published  studies  have  been  conducted  regarding  this
question  and  the  results  are  conflicting.2,5--11 In  a recent
meta-analysis,  Angeli  et  al.12 showed  that  AF  in  the  set-
ting  of  AMI  was  associated  with  a  two-fold  higher  risk  of
in-hospital  mortality,  but  the  risk  of  death  was  87%  higher
in  patients  with  new-onset  AF  than  in  those  with  permanent
AF.
The  primary  aim  of  this  study  was  to  identify  the  clinical
differences  and  prognostic  impact  of  AF  type  during  acute
coronary  syndromes  (ACS).
Methods
This  was  a  retrospective  observational  cohort  study  with
a  six-month  follow-up.  All  patients  (n=1373;  mean  age
64  years,  77.3%  male)  consecutively  admitted  to  the  coro-
nary  care  unit  of  a  single  center  with  a  diagnosis  of  ACS
between  July  2009  and  June  2012  were  included.
Diagnoses  of  ACS  and  AF  were  made  according  to  the
European  Society  of  Cardiology  guidelines.13--16 Heart  fail-
ure  was  defined  as  Killip  class  ≥2  during  hospitalization  and
as  NYHA  class  ≥2  during  follow-up.  Patients  with  AF  were
divided  according  to  the  timing  of  the  arrhythmia:  every
patient  who  presented  with  AF  for  the  first  time  (i.e.,  who
did  not  have  previously  documented  AF)  at  admission  or  dur-
ing  hospital  stay  was  considered  to  have  new-onset  AF,  while
those  with  previously  documented  AF  were  classified  as  hav-
ing  pre-existing  AF  (paroxysmal,  persistent  or  permanent).
Regarding  AF  management,  a  rhythm  control  strategy
was  defined  as  the  aim  of  restoration  and  successful  main-
tenance  of  sinus  rhythm  and  rate  control  strategy  as
acceptance  of  AF  rhythm  with  ventricular  rate  control.
The  use  of  oral  anticoagulation  and  antiarrhythmic  therapy
(amiodarone)  at  discharge  was  also  assessed.  The  man-
agement  of  each  patient  was  individualized  and  based  on
clinical  parameters.
Demographic,  clinical,  laboratory,  echocardiographic  and
coronary  angiographic  data  were  collected  prospectively
and  recorded  in  a  computerized  database,  in  accordance
with  our  department’s  protocol  for  patients  admitted  to  the
coronary  care  unit  with  ACS.
Concerning  laboratory  data,  N-terminal  pro-brain  natri-
uretic  peptide  (NT-proBNP)  values  were  obtained  within
24  hours  of  admission  and  peak  creatinine  was  considered
to  be  the  maximum  value  during  hospitalization.  Glomeru-
lar  filtration  rate  was  calculated  at  presentation  using  the
abbreviated  Modification  of  Diet  in  Renal  Disease  formula.17
The  first  echocardiogram  performed  in  hospital  was  used
to  provide  echocardiographic  data.  Right  ventricular  sys-
tolic  dysfunction  was  defined  as  tricuspid  annular  systolic
excursion  >16  mm.
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Coronary  angiographic  data  were  collected  from  angiog-
raphy  performed  during  hospital  stay.  Significant  coronary
artery  disease  on  coronary  angiography  was  defined  as  at
least  one  ≥50%  lesion  in  the  left  main  artery  and/or  ≥70%  in
other  coronary  arteries.  Multivessel  disease  was  defined  as
significant  stenosis  in  two  or  more  major  epicardial  arteries
and  coronary  revascularization  as  successful  percutaneous
or  surgical  coronary  intervention  to  restore  blood  flow.
Statistical  analysis
Univariate  analysis  of  categorical  variables  was  performed
using  the  chi-square  test,  with  results  expressed  as  per-
centages,  and  of  continuous  variables  using  the  Student’s  t
test,  with  results  expressed  as  means  ±  standard  deviation.
Analysis  of  the  therapeutic  strategy  used  to  manage  AF  was
performed  after  exclusion  of  patients  who  died  during  hos-
pital  stay.  Multivariate  logistic  analysis  was  performed  to
determine  the  independent  predictors  of  in-hospital  mor-
tality,  including  only  variables  with  statistical  significance
on  univariate  analysis.  Kaplan-Meier  analysis  was  used  to
illustrate  six-month  cumulative  mortality  according  to  the
presence  of  AF  and  AF  type.  Differences  with  p<0.05  were
considered  significant.  The  statistical  analysis  was  carried
out  using  SPSS  version  18.0.
Results
In  the  study  population  (n=1373),  AF  rhythm  was  identified
in  14.5%  patients  (n=199),  of  whom  71.4%  (n=142)  presented
new-onset  AF  and  28.6%  (n=57)  pre-existing  AF.  Patients  with
new-onset  AF,  pre-existing  AF  and  without  AF  were  stud-
ied  according  to  their  baseline  characteristics,  in-hospital
features  and  clinical  outcomes.
Baseline  characteristics  and  in-hospital  data
New-onset  AF  and  pre-existing  AF  patients  were  compared
with  those  without  AF.  The  baseline  characteristics  of  the
study  population  are  shown  in  Table  1.
AF,  either  new-onset  or  pre-existing,  was  more  frequent
in  older,  non-smoking  and  hypertensive  patients.  Although
the  proportion  of  women  was  higher  in  both  AF  types  than
in  patients  without  AF,  the  difference  was  only  significant
for  those  with  pre-existing  AF  (p=0.015).  AF  patients  had
greater  cardiovascular  disease  burden  and  were  more  likely
to  be  taking  cardiovascular  medication  at  presentation,  as
demonstrated  in  Table  1.
Clinical  information  during  hospital  stay  and  laboratory,
echocardiographic,  coronary  angiographic  and  revasculari-
zation  data  are  summarized  in  Table  2.
At  admission,  patients  with  new-onset  and  pre-existing
AF  had  higher  heart  rate  and  worse  Killip  class.  No  differ-
ences  were  found  in  systolic  blood  pressure.  Interestingly,
ACS  severity  was  related  to  AF  type:  ST-elevation  ACS
incidence  was  higher  in  new-onset  AF  (60.1%,  p=0.030),
intermediate  in  the  AF-free  group  (50.6%)  and  lower  in  pre-
existing  AF  (36.8%,  p=0.043).
During  hospitalization,  the  presence  of  AF,  regardless  of
type,  was  associated  with  worse  clinical,  laboratory  and
echocardiographic  features.  Patients  with  AF  were  more
likely  to  have  heart  failure,  lower  glomerular  filtration  rate,
higher  peak  creatinine,  lower  hemoglobin  and  higher  NT-
proBNP.  Additionally,  patients  with  AF  more  often  presented
biventricular  systolic  dysfunction,  higher  mitral  regurgita-
tion  grade  and  greater  left  atrial  diameter.  Although  the
incidence  of  respiratory  tract  infections  was  higher  in  AF
groups,  only  new-onset  AF  patients  had  significantly  higher
C-reactive  protein  levels  than  patients  without  AF.  No  differ-
ences  between  non-AF  and  AF  groups  were  found  regarding
other  arrhythmic  complications,  such  as  high  grade  atrioven-
tricular  block  or  ventricular  fibrillation.
The  presence  of  multivessel  disease  was  similar  between
groups.  Patients  with  new-onset  AF  and  pre-existing  AF  were
less  likely  to  have  significant  coronary  lesions  or  to  have
undergone  coronary  revascularization,  the  latter  due  to  the
lower  number  of  percutaneous  coronary  interventions  (PCI)
performed.
The  thromboembolic  risk  score  CHA2DS2VASc  and  the
GRACE  score  were  higher  in  patients  with  new-onset  and
pre-existing  AF  than  in  patients  without  AF.
Comparison  between  atrial  fibrillation  types
The  clinical  and  in-hospital  differences  with  statistical  sig-
nificance  between  new-onset  AF  and  pre-existing  AF  groups
are  displayed  in  Table  3.  Patients  with  new-onset  AF  were
younger  (p=0.044),  more  often  smokers  (p=0.015)  and  had
higher  body  mass  index  (p=0.003).  Concerning  medication
at  admission,  naturally,  patients  with  pre-existing  AF  were
more  frequently  taking  anticoagulants  (p<0.001)  and  renin-
angiotensin  system  modulators  (p=0.023).  As  pointed  out
earlier,  in  contrast  to  pre-existing  AF,  the  majority  of  new-
onset  AF  patients  presented  with  ST-elevation  ACS  (60.1%  vs.
36.8%,  respectively,  p=0.003).  Although  left  atrial  enlarge-
ment  was  common  in  both  AF  types,  left  atrial  diameter  on
echocardiography  was  significantly  greater  in  pre-existing  AF
(p=0.001).  In  coronary  angiography,  absence  of  significant
coronary  artery  disease  was  observed  more  in  pre-existing
AF  (p=0.034).
Regarding  management  strategies,  new-onset  AF  patients
were  more  often  treated  by  rhythm  control  during  hospi-
tal  stay  (p<0.001)  than  pre-existing  AF  patients,  as  shown
in  Table  4.  Patients  with  pre-existing  AF  treated  by  rhythm
control  were  more  likely  to  be  prescribed  antiarrhythmic
therapy  to  maintain  sinus  rhythm,  although  without  signifi-
cance.  At  discharge,  new-onset  AF  patients  were  less  often
anticoagulated  than  those  with  pre-existing  AF  (p<0.001).
Prognostic  impact  of  atrial  fibrillation  type
New-onset  AF  was  associated  with  significantly  worse  in-
hospital  adverse  outcomes  of  death,  heart  failure,  ischemic
stroke  and  major  bleeding  compared  to  patients  with  no
arrhythmia,  as  demonstrated  in  Table  5.  Except  for  heart
failure,  such  associations  were  not  present  in  the  group  with
pre-existing  AF.
Together  with  glomerular  filtration  rate  in  ml/min/
1.73  m2 (odds  ratio  [OR]  0.97,  95%  confidence  interval
[CI]  0.95--0.99,  p=0.010),  heart  failure  (OR  3.80,  95%  CI
1.22--11.86,  p=0.022)  and  ventricular  fibrillation  (OR  5.42,
95%  CI 1.29--22.87,  p=0.021),  new-onset  AF  remained  an
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Age  (years),  mean  (SD)  63  (±13)  72  (±12)  <0.001  75  (±10)  <0.001
Male, %  78.6%  71.8%  0.066  64.9%  0.015
BMI (kg/m2),  mean  (SD)  27.3  (±4.0)  28.2  (±4.9)  0.053  26.  4  (±3.2)  0.073
CV risk  factors,  %
Hypertension  61.8%  80.3%  <0.001  87.7%  <0.001
Diabetes 26.3%  32.4%  0.123  21.1%  0.376
Dyslipidemia  55.1% 55.6%  0.906  49.1%  0.375
Smoking 31.3% 16.2% <0.001 3.5% <0.001
History,  %
AMI  14.6%  21.1%  0.040  19.3%  0.326
CABG 3.7%  8.5%  0.009  3.5%  0.926
PCI 8.1%  6.3%  0.464  3.5%  0.210
Stroke 6.6%  10.6%  0.077  17.5%  0.002
Previous medication,  %
Anticoagulant  2.3% 2.2%  0.958  33.3%  <0.001
Aspirin 22.6% 38.0% <0.001  40.4%  0.002
Clopidogrel  8.2% 9.9%  0.494  10.5%  0.530
ACEI/ARB 42.0% 56.3% 0.001  73.7%  <0.001
Beta-blocker  19.8% 26.8% 0.051 33.3%  0.013
Statin 34.8% 38.7% 0.354 42.1% 0.262
Diuretic  21.6% 36.3% 0.002 38.9%  0.015
ACEI: angiotensin-converting enzyme inhibitor; AF: atrial fibrillation; AMI: acute myocardial infarction; ARB: angiotensin receptor blocker;
BMI: body mass index; CABG: coronary artery bypass grafting; CV: cardiovascular; PCI: percutaneous coronary intervention; SD: standard
deviation.
independent  predictor  of  in-hospital  mortality,  carrying  a
risk  2.67  times  higher  than  in  the  group  without  AF  (95%  CI
1.01--7.02,  p=0.047).
During  follow-up  (mean  218±92  days),  heart  failure
occurred  more  frequently  in  AF  groups  than  in  patients  with-
out  AF.  Mortality  was  higher  in  pre-existing  (p=0.014)  but  not
in  new-onset  AF,  although  the  latter  was  associated  with  a
trend  towards  higher  mortality  (6.3%  vs.  3.6%,  p=0.155).  No
differences  were  found  regarding  reinfarction  or  ischemic
stroke  during  follow-up.
Kaplan-Meier  survival  curves  (Figure  1)  illustrate  a  trend
towards  worse  prognosis  for  both  AF  groups  compared  with
no  arrhythmia,  with  significance  for  new-onset  AF  (log  rank
p<0.001)  but  not  for  pre-existing  AF  (log  rank  p=0.120).
Patients  with  new-onset  AF  discharged  in  sinus  rhythm
and  followed  in  the  outpatient  clinic  of  our  hospital  (n=33)
had  a  longer  follow-up  (mean  557±381  days).  The  recur-
rence  rate  of  AF  in  this  subgroup  during  follow-up  was  24.2%
(n=8).
Discussion
Recently,  our  group  reported  that  patients  with  new-onset
AF  in  the  context  of  ACS  had  worse  clinical  manifestations
and  adverse  prognostic  implications  during  hospitalization
and  throughout  follow-up.18 Questions  regarding  the  clinical
features  and  prognostic  impact  of  different  AF  types,  new-
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Figure  1  Kaplan-Meier  survival  curves  for  patients  with  new-
onset  AF,  pre-existing  AF  and  without  AF.  AF:  atrial  fibrillation.
study  included  a  larger  number  of  patients,  allowing  direct
comparison  between  new-onset  and  pre-existing  AF.
First,  regardless  of  type,  patients  with  AF  presented
high-risk  clinical  features  during  hospitalization,  such  as
older  age,  heart  and  renal  failure,  respiratory  tract  infec-
tions,  lower  hemoglobin,  higher  NT-proBNP,  biventricular
dysfunction,  significant  mitral  regurgitation,  less  coro-
nary  revascularization  and  higher  GRACE  risk  score.  The
bulk  of  evidence  clearly  demonstrates  that  the  pres-
ence  of  AF  in  itself  during  ACS  is  associated  with  worse
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Table  2  Clinical,  laboratory,  echocardiographic,  coronary  angiographic,  and  revascularization  data  and  risk  scores  during
hospital stay  of  patients  without  AF  compared  with  those  with  new-onset  and  pre-existing  AF.
Without  AF  (n=1174)  New-onset  AF  (n=142)  p  Pre-existing  AF  (n=57)  p
Clinical,  %
Heart  rate  (bpm)a,  mean  (SD)  75  (±17)  87  (±25)  <0.001  83  (±24)  0.025
SBP (mmHg)a,  mean  (SD)  129  (±27)  129  (±27)  0.846  135  (±30)  0.147
ST-elevation  ACS  50.6%  60.1%  0.030  36.8%  0.043
Heart failurea 18.6%  43.0%  <0.001  50.9%  <0.001
Respiratory  tract  infections  5.1%  21.6%  <0.001  17.1%  0.002
≥ grade  2  AV  block  6.1%  9.2%  0.167  8.8%  0.423
VF 4.1%  6.3%  0.214  3.5%  0.829
Blood tests,  mean  (SD)
GFR  <60  ml/min/1.73  m2,  %a 22.2%  38.7%  <0.001  43.9%  <0.001
Peak creatinine  (mg/dl)  1.2  (±0.6)  1.6  (±1.1)  <0.001  1.6  (±0.9)  0.003
Hemoglobin  (g/dl)a 13.9  (±2.1)  13.3  (±2.2)  0.001  13.4  (±2.1)  0.045
RDW (%)a 13.7  (±1.1)  13.7  (±1.2)  0.965  14.0  (±5.8)  0.698
NT-proBNP (pg/ml)  2601  (±5564)  4723  (±7757)  0.004  6430  (±5727)  <0.001
CRP (mg/l)a 16.1  (±31.9)  30.9  (±49.4)  0.001  19.3  (±26.0)  0.477
Echocardiography
LVEF ≤40%,  % 30.3% 52.5% <0.001 50.9%  0.001
RV systolic  dysfunction,  % 11.5% 4.8% <0.001  17.3%  <0.001
MR (grade  >II/IV),  % 3.9% 15.0% <0.001 13.2%  0.001
LA diameter  (mm),  mean  (SD)  41  (±5)  45  (±6)  <0.001  49  (±7)  <0.001
Coronary angiography,  %
Absence  of  significant  CAD  3.2%  6.7%  0.040  16.7%  <0.001
Multivessel disease  56.9%  62.8%  0.226  50.0%  0.368
Coronary revascularization,  %
PCI 68.5%  55.1%  0.002  55.1%  0.049
CABG 14.2%  10.9%  0.286  10.2%  0.432
Total 82.7%  65.9%  <0.001  65.3%  0.002
Risk scores
CHA2DS2VASc  score  3.2  (±1.6)  4.3  (±1.6)  <0.001  4.6  (±1.3)  <0.001
GRACE score 139  (±42)  172  (±42)  <0.001  172  (±45)  <0.001
ACS: acute coronary syndrome; AF: atrial fibrillation; AV: atrioventricular; CABG: coronary artery bypass grafting; CAD: coronary artery
disease; CRP: C-reactive protein; GFR: glomerular filtration rate; LA: left atrial; LVEF: left ventricular ejection fraction; MR: mitral regur-
gitation; NT-proBNP: N-terminal pro-brain natriuretic peptide; PCI: percutaneous coronary intervention; RDW: red blood cell distribution
width; RV: right ventricular; SBP: systolic blood pressure; SD: standard deviation; VF: ventricular fibrillation.
a At admission.
Table  3  Differences  between  new-onset  AF  and  pre-existing  AF.
New-onset  AF  (n=142)  Pre-existing  AF  (n=57)  p
Age  (years)  72  (±12)  75  (±10)  0.044
BMI (kg/m2)  28.2  (±4.9)  26.  4  (±3.2)  0.003
Smoking 16.2%  3.5%  0.015
Anticoagulant,  at  presentation  2.2%  33.3%  <0.001
ACEI/ARB, at  presentation  56.3%  73.7%  0.023
ST-elevation  ACS  60.1%  36.8%  0.003
LA diameter  45  (±6)  49  (±7)  0.001
Absence of  significant  CAD  6.7%  16.7%  0.034
ACEI: angiotensin-converting enzyme inhibitor; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; BMI: body mass index;
CAD: coronary artery disease; LA: left atrial.
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Table  4  Therapeutic  strategy  according  to  AF  type.
New-onset  AF  (n=126)  Pre-existing  AF  (n=55)  p
Rate  control  29.4%  72.7%  <0.001
Rhythm control  70.6%  27.3%  <0.001
Antiarrhythmic  at  discharge  18.0%  40.0%  0.053
Anticoagulation  at  discharge  33.3%  60.0%  0.001
AF: atrial fibrillation.
Table  5  In-hospital  and  follow-up  adverse  outcomes:  comparison  between  patients  without  AF  with  new-onset  and  pre-existing
AF groups.
Without  AF  (n=1174) New-onset  AF  (n=142) p  Pre-existing  AF  (n=57) p
In-hospital,  %
Mortality  4.2%  11.3%  <0.001  3.5%  0.806
Heart failure  27.2%  57.0%  <0.001  64.9%  <0.001
Re-infarction  2.5%  2.8%  0.803  1.8%  0.732
Ischemic stroke  0.8%  2.8%  0.020  1.8%  0.418
Major bleeding  2.3%  6.7%  0.015  0.0%  0.360
Follow-up, %
Mortality  3.6%  6.3%  0.155  10.6%  0.014
Heart failure  22.8%  41.0%  <0.001  50.0%  <0.001
Re-infarction  3.6%  4.1%  0.818  7.9%  0.177
Ischemic stroke  1.0%  2.1%  0.472  2.6%  0.818
AF: atrial fibrillation.
in-hospital  outcomes.1,2,7,19,20 The  pathophysiological  mech-
anisms  underlying  this  relation  may  differ  according  to  the
timing  of  the  arrhythmia.  It  is  well  known  that  acute  AF
complicating  ACS  is  proportional  to  the  grade  of  ischemia
and  has  a  negative  effect  on  coronary  perfusion  and  car-
diac  hemodynamics,2 and  is  a  marker  of  larger  area  of
necrosis.5,21 In  contrast,  pre-existing  AF  patients  usually
have  greater  cardiovascular  disease  burden  and  more  struc-
tural  heart  disease  owing  to  the  longer  duration  of  the
arrhythmia.7 Indeed,  in  our  study,  patients  with  pre-existing
AF  were  older,  more  likely  to  be  taking  cardiovascular  medi-
cations  at  admission  and  had  greater  left  atrial  diameter  on
echocardiography  than  patients  with  new-onset  AF.
Second,  unlike  in  previous  studies,5--7 the  most  frequently
encountered  type  was  new-onset  AF,  which  was  found  in
more  than  two-thirds  of  AF  patients.  This  could  be  due  to
a  bias  related  to  the  definition  used,  since  patients  without
AF  history  who  were  admitted  in  AF  rhythm  were  labeled  as
new-onset  AF,  although  the  timing  in  such  cases  could  not
be  determined  with  certainty  and,  as  such,  they  could  have
been  misclassified.  Regarding  management,  the  majority  of
these  patients  promptly  and  successfully  returned  to  sinus
rhythm  during  hospitalization,  which  favors  correct  classifi-
cation  as  new-onset  AF.
Third,  in  our  study,  the  main  differences  at  presen-
tation  between  AF  types  were  related  to  ACS  severity,
left  atrial  diameter  and  coronary  angiography  details.  As
pointed  out  above,7,18 ST-segment  elevation  ACS  is  a  pre-
dictor  of  new-onset  AF,  probably  because  the  myocardial
ischemic  burden,  and  hence  the  arrhythmogenic  substrate,
are  greater  in  this  subgroup.9 The  pathogenesis  of  AF
in  this  context  is  multifactorial  and  may  include  atrial
ischemia  or  infarction,  ventricular  dysfunction,  pericardial
inflammation,  acute  hypoxia,  ionic  disturbances,  and  neu-
rohormonal  and  autonomic  nervous  system  activation.22--24
Left  atrial  diameter  was  significantly  greater  in  pre-existing
AF  patients,  reflecting  the  progressive  atrial  dilatation  and
myocardial  remodeling  that  occurs  with  AF  evolution.  It
may  represent  a marker  of  arrhythmia  duration,  acting  as
a  substrate  for  AF  initiation  and  maintenance.10 Signifi-
cant  coronary  artery  disease  on  coronary  angiography  was
more  often  absent  in  both  subtypes,  although  in  a  higher
proportion  in  pre-existing  AF  patients.  In  fact,  AF  can  predis-
pose  to  AMI  without  atherosclerotic  plaque  rupture  through
two  mechanisms:  coronary  occlusion  by  a  thromboembolic
event  or  a  mismatch  between  myocardial  oxygen  supply
and  demand  caused  by  the  elevated  and  irregular  heart
rate.14,25 We  hypothesize  that  AF  type  might  be  a  marker
of  the  pathophysiologic  mechanism  underlying  myocardial
infarction:  probably,  acute  plaque  rupture  is  more  common
in  new-onset  AF  and  thromboembolism  in  pre-existing  AF.
Fourth,  short-  and  long-term  prognosis  differed  according
to  AF  type.  New-onset  AF  conferred  worse  clinical  outcomes
and  prognosis  during  hospital  stay,  while  pre-existing  AF
was  associated  with  mortality  during  follow-up,  similar  find-
ings  to  the  data  published  by  Lau  et  al.7 The  link  between
new-onset  AF  and  ST-segment  elevation  ACS  may  in  part
explain  the  worse  in-hospital  prognosis.  Unlike  pre-existing
AF,  which  does  not  imply  an  acute  change  in  hemodynamic
status  and  is  therefore  not  associated  with  worse  prognosis
during  hospitalization  for  ACS,  new-onset  AF  acutely  com-
promises  hemodynamic  status  and,  as  such,  implies  worse
clinical  in-hospital  course.  In  contrast,  long-term  mortal-
ity  is  higher  in  pre-existing  AF,  reflecting  the  existence  of
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chronic  structural  and  functional  heart  disease.26 Studies
on  the  effect  of  AF  type  on  prognosis  after  myocardial
infarction  show  conflicting  results.2,5--11 The  heterogene-
ity  of  patients  included  in  each  study,  and  the  substantial
improvement  in  ACS  treatment  in  recent  years  with  the
widespread  use  of  PCI  and  the  emergence  of  new  drug  ther-
apies,  could  explain  the  dissimilarities  in  the  clinical  impact
of  AF  type.
Finally,  in  our  study,  successful  AF  rhythm  management
predominated  in  patients  with  new-onset  AF  and  rate  con-
trol  strategy  was  preferred  in  patients  with  pre-existing
AF,  as  would  be  expected,  since  the  latter  were  older  and
had  larger  left  atrial  diameter,  recognized  factors  for  AF
recurrence,  or  were  already  on  rate  control  for  perma-
nent  AF.  Regarding  antithrombotic  therapy  at  discharge,
theoretically,  patients  with  pre-existing  AF  should  have
been  medicated  with  oral  anticoagulation,  since  they  all
had  CHA2DS2VASc  scores  ≥2.  Unlike  primary  AF,  the  antic-
ipated  bleeding  risk  is  higher  in  post-ACS  patients  due  to
the  concomitant  use  of  dual  antiplatelet  therapy,  which  is
recommended  by  the  current  guidelines  for  at  least  one
month  and  ideally  up  to  one  year  after  ACS.13 While  triple
antithrombotic  therapy  appears  to  be  safe  and  effective  in
the  short  term  (30  days),  prolonged  triple  therapy  (one  year)
is  associated  with  an  excessive  major  bleeding  risk.27--29
We  reported  that  40%  of  patients  with  pre-existing  AF  did
not  receive  anticoagulation  at  discharge.  The  occurrence
of  bleeding  complications  during  hospitalization  and  the
presence  of  high  bleeding  risk  were  the  main  factors  that
precluded  triple  antithrombotic  therapy.  Lopes  et  al.,30 in
a  large  registry  including  69  225  patients  with  AMI,  found
similar  results,  showing  that  fewer  than  50%  of  patients
with  pre-existing  AF  received  warfarin  and  only  14.6%  were
treated  with  triple  antithrombotic  therapy  at  discharge.
In  routine  practice  and  in  contrast  to  recommendations,
older  patients  with  AF  and  ACS  who  undergo  PCI  are  more
likely  to  receive  dual  antiplatelet  therapy  rather  than  triple
antithrombotic  therapy.31,32 In  the  WOEST  trial,33 the  use  of
clopidogrel  without  aspirin  in  patients  receiving  concomi-
tant  oral  anticoagulants  and  undergoing  PCI  was  associated
with  a  significant  reduction  in  bleeding  complications  and  no
increase  in  the  rate  of  thrombotic  events  within  one  year  of
intervention,  posing  the  question  whether  high  bleeding  risk
patients  with  ACS  should  be  treated  with  single  antiplatelet
therapy  plus  anticoagulation.  In  our  study,  patients  with
new-onset  AF  were  even  less  likely  to  be  discharged  with
anticoagulation  (only  one  third).  In  contrast  to  patients  with
pre-existing  AF,  the  approach  to  anticoagulation  in  those
with  new-onset  AF  during  ACS  is  far  less  clear.  Studies  report
a  non-negligible  recurrence  rate  of  new-onset  AF  that  varies
between  10  and  34%,34--37 a  similar  value  to  the  24.2%  we
described  in  the  subgroup  of  patients  discharged  in  sinus
rhythm  followed  in  our  outpatient  clinic.  Asanin  et  al.37
found  that  AF  recurred  more  frequently  soon  after  hospital
discharge  (<3  months)  in  patients  who  had  longer  duration  AF
episodes  (>3.5  hours)  within  48  hours  of  myocardial  infarc-
tion.  Furthermore,  patients  with  new-onset  AF  are  also  more
likely  to  suffer  stroke  during  follow-up.  Zusman  et  al.35
reported  an  annual  incidence  of  ischemic  stroke  of  4.4%  vs.
0.2%  in  the  non-AF  group,  and  Siu  et  al.34 found  incidences
of  10.2%  and  7.5%,  respectively,  during  the  first  and  sec-
ond  year  of  follow-up,  in  patients  with  transient  AF  during
inferior  AMI  when  they  were  treated  with  antiplatelet  ther-
apy  alone.  Asanin  et  al.37 described  some  predictors  of
stroke  in  patients  with  a  history  of  new-onset  AF,  including
absence  of  anticoagulation  at  discharge,  recurrence  of  AF
and  heart  failure  during  follow-up.  To  summarize,  although
new-onset  AF  in  the  setting  of  ACS  can  be  transient,  it
should  not  be  regarded  as  a benign  complication  of  the  acute
event,  since  it  carries  a  substantial  future  risk  for  recurrence
and  stroke.  Therefore,  oral  anticoagulation  should  also  be
strongly  considered  in  patients  with  new-onset  AF.
Limitations
There  are  several  limitations  to  be  considered  in  the  inter-
pretation  of  our  study.  First,  this  was  a retrospective,
observational  and  non-randomized  study  conducted  at a  sin-
gle  hospital,  and  as  such,  both  identified  and  unidentified
confounders  may  have  influenced  the  outcomes.  As  pointed
out  above,  new-onset  AF  patients  could  have  been  misclas-
sified.  Second,  our  results  are  limited  by  the  relatively  small
numbers  of  patients  studied  with  new-onset  and  pre-existing
AF.  Finally,  most  variables  were  determined  by  consulting
medical  records  that  could  have  been  incomplete.
Conclusions
In  summary,  new-onset  AF  was  more  common  in  patients
presenting  with  ST-elevation  ACS  who  had  high-risk  clinical
features  and  worse  prognosis  during  hospitalization,  proba-
bly  reflecting  a  greater  degree  of  ischemia.  In  turn,  patients
with  pre-existing  AF  had  greater  mortality  throughout
follow-up,  reflecting  the  existence  of  established  structural
heart  disease.
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